AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 42 min read$GILD

O'Day Daniel Patrick sold $2.0M of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 15,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $130.31 ($129.66–$131.34, $1.95M total) across 3 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Day Daniel Patrick
Published Aug 4, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new earnings, guidance, regulatory, or product information that would change valuation assumptions.

02

Market read

For trading, this is primarily a sentiment/positioning datapoint rather than a fundamental catalyst.

03

What to watch

Traders may focus on whether this sale is part of a larger, recurring pattern versus a one-off tranche; this brief only covers the disclosed sale size and timing.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-04, covering sales executed 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Gilead Sciences, filed on 2026-08-04, detailing sales by CEO Daniel Patrick O'Day.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

Gilead CEO O'Day sold about $1.95M of GILD shares in an open-market transaction under a pre-arranged 10b5-1 plan on 2026-08-03.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and the article provides no new company-specific operational or financial information.

Market effects

Sector

No clear sector read-through; this is company-specific insider selling without new guidance or trial/regulatory updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider selling can sometimes coincide with private information, but the explicit 10b5-1 pre-arranged nature reduces that signal.

Key entities

  • issuer
    Gilead Sciences, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    O'Day Daniel Patrick

    Chairman & CEO who executed open-market sales under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$GILDMed

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.

medicaldaily.com7 min
AUG 7
$GILDMedAI 8/10

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences (GILD) reported Q2 2026 non-GAAP loss per share of $6.75 and revenue of $7.8B, both above consensus. Management raised 2026 product sales guidance excluding Veklury to $29.8B-$30.1B and lifted HIV sales growth outlook to 9%-10%. CEO cited HIV and PrEP strength, Trodelvy growth, and ongoing anito-cel launch prep.

zacks.com6 min
AUG 6
$MRKMed

MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

Merck & Co (MSD) and Gilead Sciences ended the Phase III KEYNOTE-D46/EVOKE-03 trial in frontline PD-L1-expressing NSCLC after an external data monitoring committee projected the Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) would not significantly improve overall survival versus Keytruda alone. Trodelvy-Keytruda showed nonsignificant PFS benefit and no new safety issues. Trodelvy Q2 2026 sales rose 26% to $457m.

yahoo.com3 min
AUG 5
$GILDMed

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

Gilead Sciences (GILD) reported Q2 CY2026 revenue of $7.80 billion, up 10.2% year over year, and a non-GAAP loss of $6.75 per share. Full-year revenue guidance was $30.25 billion at the midpoint, 0.6% below analysts’ estimates. Management cited HIV franchise strength, including Biktarvy and PrEP, plus Trodelvy growth, while noting margin pressure from acquisition-related R&D costs.

stockstory.org4 min